The increasing prevalence of obesity has prompted greater interest in effective weight-loss treatments. Semaglutide, a GLP-1 receptor agonist originally developed to treat type 2 diabetes, has emerged as a promising option for weight management in people without diabetes. Clinical trials have demonstrated its efficacy in promoting weight loss, making it a valuable tool against obesity.
Semaglutide mimics the naturally occurring hormone GLP-1, which regulates appetite and insulin secretion. By boosting insulin production and slowing gastric emptying, semaglutide helps individuals feel full longer, reducing overall calorie intake. These processes have been shown to cause significant weight loss, with some studies reporting reductions up to 14.9% of body weight over 68 weeks.
Approving semaglutide for weight loss in non-diabetic individuals marks a major advancement in obesity treatment. In Singapore, Wegovy—a higher-dose form of semaglutide—is approved for patients with a BMI of 30 or more, and those with a BMI of 27 or more who have weight-related medical issues like high blood pressure or heart disease. This approval reflects growing recognition for effective weight-loss therapies beyond traditional lifestyle changes.
Healthcare providers have seen positive outcomes in patients using semaglutide for weight loss. Dr. Khoo Chin Meng, head and senior consultant at National University Hospital’s endocrinology division, observed that semaglutide is more effective than existing obesity drugs and generally well-tolerated. While acknowledging its high cost, Dr. Khoo highlighted its potential to help individuals lose significant weight, improving obesity-related health conditions.
Off-label use of semaglutide for weight loss in non-diabetic individuals should be viewed as a pragmatic response to the obesity epidemic. Given limited effective weight-loss drugs, semaglutide offers a viable option for those struggling with obesity. Its use should be managed by healthcare professionals who can monitor side effects and ensure benefits outweigh risks.
In summary, semaglutide represents a promising obesity management tool. Its ability to promote weight loss in non-diabetic individuals offers hope for many seeking better health and quality of life. With proper medical supervision, semaglutide can be a valuable part of comprehensive obesity treatment.